Arrangement to Conclude Proceedings, Subject to Conditions in accordance With Section B to Chapter 9A of the Securities Law 5728-1968 That was drawn and entered into on August 13 2018, between the following parties:Arrangement to Conclude Proceedings • August 20th, 2018 • BiondVax Pharmaceuticals Ltd. • Biological products, (no disgnostic substances)
Whereas the Suspect was investigated for suspicion of violating the Securities Law 5728-1968, while serving as CEO of BiondVax Pharmaceuticals Ltd. and as director in the Company;
